Which drugs went off patent in 2025?
Four blockbuster drugs with $20.3B in 2025 worldwide sales lost US exclusivity in 2025, led by Entresto (Novartis, $7.7B). One is a small-molecule drug that went generic and three are biologics that faced biosimilars.
| Drug | Company | Area | 2025 sales | Date basis | US copies | Medicare price |
|---|---|---|---|---|---|---|
| Entresto | Novartis | Cardiometabolic | $7.7B | Generics launched | Copies on the US market | 2026 · −53% |
| Stelara | Johnson & Johnson | Immunology | $6.1B | Generics launched | Copies on the US market | 2026 · −66% |
| Prolia | Amgen | Other | $4.4B | Generics launched | Copies on the US market | – |
| Xgeva | Amgen | Oncology | $2.1B | Generics launched | Copies on the US market | – |
Every date here is fixed by a launch, settlement, court ruling or company guidance. Each drug's page has the sources.
| Company | Drugs | 2025 revenue from them | Share of company |
|---|---|---|---|
| Novartis | Entresto | $7.7B | 14% |
| Amgen | Prolia and Xgeva | $6.5B | 18% |
| Johnson & Johnson | Stelara | $6.1B | 6.5% |
For shared drugs, each company is credited with the revenue it reports, so nothing is counted twice. Share is of the company's total 2025 revenue.
US generics and biosimilars could launch from 2025. Generic launches usually take most of a drug's US volume within months. Biosimilars usually erode a biologic's sales more gradually, because they are harder to make and switching takes longer. Entresto and Stelara were also selected for Medicare price negotiation, which can cut Medicare revenue before or alongside US copies.
US exclusivity can end earlier or later than these dates if a court ruling, settlement or new patent changes the picture. See what happened to sales after past patent cliffs →